Early Allograft Dysfunction and Liver Transplant Outcomes: A Single Center Retrospective Study
Abstract Background Early allograft dysfunction (EAD) had been related to poor transplant outcomes during the early years of liver transplantation. We sought to determine the incidence of EAD at our unit and to evaluate its impact on posttransplant outcomes. Methods This single-center retrospective...
Gespeichert in:
Veröffentlicht in: | Transplantation proceedings 2012-10, Vol.44 (8), p.2449-2451 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2451 |
---|---|
container_issue | 8 |
container_start_page | 2449 |
container_title | Transplantation proceedings |
container_volume | 44 |
creator | Salvalaggio, P.R Felga, G.E Afonso, R.C Ferraz-Neto, B.H |
description | Abstract Background Early allograft dysfunction (EAD) had been related to poor transplant outcomes during the early years of liver transplantation. We sought to determine the incidence of EAD at our unit and to evaluate its impact on posttransplant outcomes. Methods This single-center retrospective study included primary deceased donor liver grafts transplanted under the Model for End-Stage Liver Disease system. EAD was defined as a peak values of aminotransferase >2000 IU/mL during the first week or an International Normalized Ratio of ≥1.6 and/or bilirubin ≥10 mg/dL at day 7. The main endpoints were patient and graft survivals. Results Patients with versus without EAD showed similar recipient characteristics. Donors who experienced EAD who comprises 56% of recipients were heavier with larger body mass indices. EAD was an independent risk factor for allograft loss. Most retransplants were performed early due to nonfunction. The primary nonfunction rate among subjects with versus without EAD were 7% and 12% respectively ( P < .05). Patient survival among those with EAD was 87.4%, while without EAD it was 90% ( P = NS) with graft survivals of 81.4% and 88.7% respectively ( P < .05). Conclusion Patients with EAD show a significantly higher risk for allograft loss, but with a comparable survival after transplantation. Despite their worse outcomes, it seems that not all of these recipients behave equally. |
doi_str_mv | 10.1016/j.transproceed.2012.08.002 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1082238265</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041134512008408</els_id><sourcerecordid>1082238265</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-45849c4bd913b26dbc91d5e4f88e1d5a5198b3bd3661ec4975f7c3da4e21fc103</originalsourceid><addsrcrecordid>eNqNkl2L1DAUhoMo7rj6F6QIgjet-Won3QthmF13hYEFZ701pMnpkrGTjkk70H_vqTOL4pVXSchzznt4OIS8Y7RglFUfd8UQTUiH2FsAV3DKeEFVQSl_RhZMLUXOKy6ekwWlkuVMyPKCvEppR_HNpXhJLrigvKrYckG-35jYTdmq6_rHaNohu55SOwY7-D5kJrhs448Qs4ffgZ0JQ3Y_DrbfQ7rKVtnWh8cOsjWEAaGvMMQ-HQCLj5Bth9FNr8mL1nQJ3pzPS_Lt883D-i7f3N9-Wa82uZVVOeSyVLK2snE1Ew2vXGNr5kqQrVKAF1OyWjWicQKHBivrZdkurXBGAmetZVRckg-nvijl5whp0HufLHQ4MfRj0owqzoXiVYno1Qm1OGyK0OpD9HsTJ4T07Ffv9N9-9exXU6XRLxa_PeeMzR7_nkqfhCLw_gyYZE3XYiPr0x-uKqs5A7nrEwdo5egh6mQ9BAvORxSoXe__b55P_7SxnQ8ek3_ABGnXjzGgd810whq9nTdiXgjGKVWSKvELSRq1UA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1082238265</pqid></control><display><type>article</type><title>Early Allograft Dysfunction and Liver Transplant Outcomes: A Single Center Retrospective Study</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Salvalaggio, P.R ; Felga, G.E ; Afonso, R.C ; Ferraz-Neto, B.H</creator><creatorcontrib>Salvalaggio, P.R ; Felga, G.E ; Afonso, R.C ; Ferraz-Neto, B.H</creatorcontrib><description>Abstract Background Early allograft dysfunction (EAD) had been related to poor transplant outcomes during the early years of liver transplantation. We sought to determine the incidence of EAD at our unit and to evaluate its impact on posttransplant outcomes. Methods This single-center retrospective study included primary deceased donor liver grafts transplanted under the Model for End-Stage Liver Disease system. EAD was defined as a peak values of aminotransferase >2000 IU/mL during the first week or an International Normalized Ratio of ≥1.6 and/or bilirubin ≥10 mg/dL at day 7. The main endpoints were patient and graft survivals. Results Patients with versus without EAD showed similar recipient characteristics. Donors who experienced EAD who comprises 56% of recipients were heavier with larger body mass indices. EAD was an independent risk factor for allograft loss. Most retransplants were performed early due to nonfunction. The primary nonfunction rate among subjects with versus without EAD were 7% and 12% respectively ( P < .05). Patient survival among those with EAD was 87.4%, while without EAD it was 90% ( P = NS) with graft survivals of 81.4% and 88.7% respectively ( P < .05). Conclusion Patients with EAD show a significantly higher risk for allograft loss, but with a comparable survival after transplantation. Despite their worse outcomes, it seems that not all of these recipients behave equally.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2012.08.002</identifier><identifier>PMID: 23026617</identifier><identifier>CODEN: TRPPA8</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Alanine Transaminase - blood ; Aspartate Aminotransferases - blood ; Bilirubin - blood ; Biological and medical sciences ; Biomarkers - blood ; Brazil - epidemiology ; Chi-Square Distribution ; Female ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Graft Survival ; Humans ; Incidence ; Kaplan-Meier Estimate ; Liver Transplantation - adverse effects ; Liver Transplantation - mortality ; Male ; Medical sciences ; Primary Graft Dysfunction - blood ; Primary Graft Dysfunction - epidemiology ; Primary Graft Dysfunction - mortality ; Proportional Hazards Models ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Surgery ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Time Factors ; Tissue, organ and graft immunology ; Treatment Outcome</subject><ispartof>Transplantation proceedings, 2012-10, Vol.44 (8), p.2449-2451</ispartof><rights>Elsevier Inc.</rights><rights>2012 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-45849c4bd913b26dbc91d5e4f88e1d5a5198b3bd3661ec4975f7c3da4e21fc103</citedby><cites>FETCH-LOGICAL-c465t-45849c4bd913b26dbc91d5e4f88e1d5a5198b3bd3661ec4975f7c3da4e21fc103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.transproceed.2012.08.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,3550,23930,23931,25140,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26561016$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23026617$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salvalaggio, P.R</creatorcontrib><creatorcontrib>Felga, G.E</creatorcontrib><creatorcontrib>Afonso, R.C</creatorcontrib><creatorcontrib>Ferraz-Neto, B.H</creatorcontrib><title>Early Allograft Dysfunction and Liver Transplant Outcomes: A Single Center Retrospective Study</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Abstract Background Early allograft dysfunction (EAD) had been related to poor transplant outcomes during the early years of liver transplantation. We sought to determine the incidence of EAD at our unit and to evaluate its impact on posttransplant outcomes. Methods This single-center retrospective study included primary deceased donor liver grafts transplanted under the Model for End-Stage Liver Disease system. EAD was defined as a peak values of aminotransferase >2000 IU/mL during the first week or an International Normalized Ratio of ≥1.6 and/or bilirubin ≥10 mg/dL at day 7. The main endpoints were patient and graft survivals. Results Patients with versus without EAD showed similar recipient characteristics. Donors who experienced EAD who comprises 56% of recipients were heavier with larger body mass indices. EAD was an independent risk factor for allograft loss. Most retransplants were performed early due to nonfunction. The primary nonfunction rate among subjects with versus without EAD were 7% and 12% respectively ( P < .05). Patient survival among those with EAD was 87.4%, while without EAD it was 90% ( P = NS) with graft survivals of 81.4% and 88.7% respectively ( P < .05). Conclusion Patients with EAD show a significantly higher risk for allograft loss, but with a comparable survival after transplantation. Despite their worse outcomes, it seems that not all of these recipients behave equally.</description><subject>Alanine Transaminase - blood</subject><subject>Aspartate Aminotransferases - blood</subject><subject>Bilirubin - blood</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Brazil - epidemiology</subject><subject>Chi-Square Distribution</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Graft Survival</subject><subject>Humans</subject><subject>Incidence</subject><subject>Kaplan-Meier Estimate</subject><subject>Liver Transplantation - adverse effects</subject><subject>Liver Transplantation - mortality</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Primary Graft Dysfunction - blood</subject><subject>Primary Graft Dysfunction - epidemiology</subject><subject>Primary Graft Dysfunction - mortality</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Surgery</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Time Factors</subject><subject>Tissue, organ and graft immunology</subject><subject>Treatment Outcome</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkl2L1DAUhoMo7rj6F6QIgjet-Won3QthmF13hYEFZ701pMnpkrGTjkk70H_vqTOL4pVXSchzznt4OIS8Y7RglFUfd8UQTUiH2FsAV3DKeEFVQSl_RhZMLUXOKy6ekwWlkuVMyPKCvEppR_HNpXhJLrigvKrYckG-35jYTdmq6_rHaNohu55SOwY7-D5kJrhs448Qs4ffgZ0JQ3Y_DrbfQ7rKVtnWh8cOsjWEAaGvMMQ-HQCLj5Bth9FNr8mL1nQJ3pzPS_Lt883D-i7f3N9-Wa82uZVVOeSyVLK2snE1Ew2vXGNr5kqQrVKAF1OyWjWicQKHBivrZdkurXBGAmetZVRckg-nvijl5whp0HufLHQ4MfRj0owqzoXiVYno1Qm1OGyK0OpD9HsTJ4T07Ffv9N9-9exXU6XRLxa_PeeMzR7_nkqfhCLw_gyYZE3XYiPr0x-uKqs5A7nrEwdo5egh6mQ9BAvORxSoXe__b55P_7SxnQ8ek3_ABGnXjzGgd810whq9nTdiXgjGKVWSKvELSRq1UA</recordid><startdate>20121001</startdate><enddate>20121001</enddate><creator>Salvalaggio, P.R</creator><creator>Felga, G.E</creator><creator>Afonso, R.C</creator><creator>Ferraz-Neto, B.H</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20121001</creationdate><title>Early Allograft Dysfunction and Liver Transplant Outcomes: A Single Center Retrospective Study</title><author>Salvalaggio, P.R ; Felga, G.E ; Afonso, R.C ; Ferraz-Neto, B.H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-45849c4bd913b26dbc91d5e4f88e1d5a5198b3bd3661ec4975f7c3da4e21fc103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Alanine Transaminase - blood</topic><topic>Aspartate Aminotransferases - blood</topic><topic>Bilirubin - blood</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Brazil - epidemiology</topic><topic>Chi-Square Distribution</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Graft Survival</topic><topic>Humans</topic><topic>Incidence</topic><topic>Kaplan-Meier Estimate</topic><topic>Liver Transplantation - adverse effects</topic><topic>Liver Transplantation - mortality</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Primary Graft Dysfunction - blood</topic><topic>Primary Graft Dysfunction - epidemiology</topic><topic>Primary Graft Dysfunction - mortality</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Surgery</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Time Factors</topic><topic>Tissue, organ and graft immunology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salvalaggio, P.R</creatorcontrib><creatorcontrib>Felga, G.E</creatorcontrib><creatorcontrib>Afonso, R.C</creatorcontrib><creatorcontrib>Ferraz-Neto, B.H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salvalaggio, P.R</au><au>Felga, G.E</au><au>Afonso, R.C</au><au>Ferraz-Neto, B.H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early Allograft Dysfunction and Liver Transplant Outcomes: A Single Center Retrospective Study</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2012-10-01</date><risdate>2012</risdate><volume>44</volume><issue>8</issue><spage>2449</spage><epage>2451</epage><pages>2449-2451</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><coden>TRPPA8</coden><abstract>Abstract Background Early allograft dysfunction (EAD) had been related to poor transplant outcomes during the early years of liver transplantation. We sought to determine the incidence of EAD at our unit and to evaluate its impact on posttransplant outcomes. Methods This single-center retrospective study included primary deceased donor liver grafts transplanted under the Model for End-Stage Liver Disease system. EAD was defined as a peak values of aminotransferase >2000 IU/mL during the first week or an International Normalized Ratio of ≥1.6 and/or bilirubin ≥10 mg/dL at day 7. The main endpoints were patient and graft survivals. Results Patients with versus without EAD showed similar recipient characteristics. Donors who experienced EAD who comprises 56% of recipients were heavier with larger body mass indices. EAD was an independent risk factor for allograft loss. Most retransplants were performed early due to nonfunction. The primary nonfunction rate among subjects with versus without EAD were 7% and 12% respectively ( P < .05). Patient survival among those with EAD was 87.4%, while without EAD it was 90% ( P = NS) with graft survivals of 81.4% and 88.7% respectively ( P < .05). Conclusion Patients with EAD show a significantly higher risk for allograft loss, but with a comparable survival after transplantation. Despite their worse outcomes, it seems that not all of these recipients behave equally.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>23026617</pmid><doi>10.1016/j.transproceed.2012.08.002</doi><tpages>3</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0041-1345 |
ispartof | Transplantation proceedings, 2012-10, Vol.44 (8), p.2449-2451 |
issn | 0041-1345 1873-2623 |
language | eng |
recordid | cdi_proquest_miscellaneous_1082238265 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Alanine Transaminase - blood Aspartate Aminotransferases - blood Bilirubin - blood Biological and medical sciences Biomarkers - blood Brazil - epidemiology Chi-Square Distribution Female Fundamental and applied biological sciences. Psychology Fundamental immunology Graft Survival Humans Incidence Kaplan-Meier Estimate Liver Transplantation - adverse effects Liver Transplantation - mortality Male Medical sciences Primary Graft Dysfunction - blood Primary Graft Dysfunction - epidemiology Primary Graft Dysfunction - mortality Proportional Hazards Models Retrospective Studies Risk Assessment Risk Factors Surgery Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Time Factors Tissue, organ and graft immunology Treatment Outcome |
title | Early Allograft Dysfunction and Liver Transplant Outcomes: A Single Center Retrospective Study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T23%3A39%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20Allograft%20Dysfunction%20and%20Liver%20Transplant%20Outcomes:%20A%20Single%20Center%20Retrospective%20Study&rft.jtitle=Transplantation%20proceedings&rft.au=Salvalaggio,%20P.R&rft.date=2012-10-01&rft.volume=44&rft.issue=8&rft.spage=2449&rft.epage=2451&rft.pages=2449-2451&rft.issn=0041-1345&rft.eissn=1873-2623&rft.coden=TRPPA8&rft_id=info:doi/10.1016/j.transproceed.2012.08.002&rft_dat=%3Cproquest_cross%3E1082238265%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1082238265&rft_id=info:pmid/23026617&rft_els_id=S0041134512008408&rfr_iscdi=true |